about
Searching for the physiological role of glucose-dependent insulinotropic polypeptideGlucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.Interdependency of EGF and GLP-2 Signaling in Attenuating Mucosal Atrophy in a Mouse Model of Parenteral NutritionPatients With Long-QT Syndrome Caused by Impaired hERG-Encoded Kv11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia.The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist.GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors.Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure.Diabetic intestinal growth adaptation and glucagon-like peptide 2 in the rat: effects of dietary fibre.Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon.Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass.The anorexic hormone Peptide YY3-36 is rapidly metabolized to inactive Peptide YY3-34 in vivoHeterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides.Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptorsN-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptorRapid gut growth but persistent delay in digestive function in the postnatal period of preterm pigsOxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma.A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patientsFructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans.Acute effects of glucagon-like peptide-1, GLP-19-36 amide, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers.Glutamate prevents intestinal atrophy via luminal nutrient sensing in a mouse model of total parenteral nutrition.Continuous parenteral and enteral nutrition induces metabolic dysfunction in neonatal pigsMeasurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide.Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system.GLP-1 amidation efficiency along the length of the intestine in mice, rats and pigs and in GLP-1 secreting cell lines.Effects of Peripheral Neurotensin on Appetite Regulation and Its Role in Gastric Bypass Surgery.Dynamics of glucagon secretion in mice and rats revealed using a validated sandwich ELISA for small sample volumes.In vivo and in vitro degradation of peptide YY3-36 to inactive peptide YY3-34 in humans.Effects of exogenous glucagon-like peptide-2 and distal bowel resection on intestinal and systemic adaptive responses in ratsGlucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonates.Stability of glucagon-like peptide 1 and glucagon in human plasma.Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept.Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion.Glucagon-like peptide-1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men.Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty.The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin.Glucagon-like peptide 2 treatment may improve intestinal adaptation during weaning.
P50
Q26749221-C9BCC3B4-6882-48E2-9A03-D71E8EE33D6AQ32085854-6EA6BD71-793F-4305-A024-0C548E5FD5D5Q33600424-3FC57200-223E-495A-8BA1-F92B02B8D252Q33625684-7D0CD93F-ABF9-49DE-9617-E29A257C75E9Q34104467-7BCBD9A6-C872-49FC-9F1F-D0945E65DD4FQ34367809-1ABD7A40-5C5E-4940-9E8A-E9A2C5C158F7Q35357446-0D19CB09-23B1-4C3A-B929-FF704902FE73Q35357569-5D491621-82CF-46AC-BBA0-E209CAA3DEFAQ35361126-FD1A1268-9028-4722-AEF8-A66D7FFFE08CQ35596753-116B31F7-8AB3-402B-AE03-EE8D128B575DQ35652968-CD4DD224-2AF1-485C-9C26-2DDC8E0460F6Q35932686-A767A1F2-85B1-4F32-9B4F-D2A5460A08C7Q36004364-D0A3A054-F2D6-40E5-A5F2-52B6AFE05379Q36388433-ECE1EDCD-C847-4267-91DB-B558C0A2C5F0Q36533318-6AA20907-CA49-4549-859B-8B066529B15AQ36599662-B19CBD2C-901A-49D9-8081-089F0E846C95Q36811324-62456652-48AF-4815-AC77-A4DF940E0233Q37009157-107007DE-7175-44C4-AC13-8170672DF4C7Q37247764-DEC9B9D0-4961-4D81-AC34-BB51D9C64E98Q37655941-94F28C62-75C2-4DC4-A620-71F18C071AE8Q37670232-8D109847-EFD6-41A1-ADA4-C0A77830EB1BQ37702934-9539EF39-64FF-4944-B407-41F45E1F9C6BQ37724046-CD67FDE3-5979-42C9-8DA2-B5FDBC2DD079Q38333466-3B88C1A4-C259-422C-8A53-B33A3375E539Q38784664-2D8D0EB0-D4C9-4504-A514-6E3114919A11Q39028239-A0C81D9B-7408-4A9B-B853-D25A84BC52D6Q39435376-1ED50BEE-E486-4814-9C83-D47B2C718911Q39721905-8C9D7E31-C6AD-4BF5-8307-31A32DCFFFA4Q40953070-31306BFF-5582-4FF2-9607-63282ED79CB0Q41106209-34C3B946-56A8-4176-A300-BE1B4A285864Q41393541-F7538D36-6964-48F1-8178-2E6127A786D6Q41571544-C3CD5CAD-5AEA-498D-8773-1BB72F7529E8Q41662018-CE4AA7B7-E553-41EA-BA9F-FCA8AFA59429Q42128258-21FD972D-E952-4DEA-8485-4CDD3D5D08BDQ42186713-4AA4DF60-349A-4671-9D5F-CC538A674941Q42464329-76DE28E3-1911-4A0A-B821-92FA1D0F577CQ42468122-4573F152-F4D9-48C2-A5E7-573007CDB407Q43094716-9B7AE996-F96F-4686-9145-EB806E449197Q43181109-5A3B687F-8311-45DC-B09B-DA926B6AA034Q43314976-71796797-8EBA-4017-AAE7-332690A206DA
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Bolette Hartmann
@ast
Bolette Hartmann
@en
Bolette Hartmann
@es
Bolette Hartmann
@nl
Bolette Hartmann
@sl
type
label
Bolette Hartmann
@ast
Bolette Hartmann
@en
Bolette Hartmann
@es
Bolette Hartmann
@nl
Bolette Hartmann
@sl
altLabel
Hartmann B
@en
prefLabel
Bolette Hartmann
@ast
Bolette Hartmann
@en
Bolette Hartmann
@es
Bolette Hartmann
@nl
Bolette Hartmann
@sl
P106
P1153
56970675400
7201381301
P31
P496
0000-0001-8509-2036